Data from a Phase 1 Trial of HighField Biopharmaceuticals' HF1K16 Show the New Immuno ...
HighField Biopharmaceuticals presented positive safety and efficacy findings from its Phase 1 study of HF1K16 (K16), targeting myeloid-derived suppressor cells (MDSCs), at the ESMO Congress 2024. The study showed significant immune modulation and efficacy, with several R/R glioma patients surviving over 2 years.
Related Clinical Trials
Reference News
Data from a Phase 1 Trial of HighField Biopharmaceuticals' HF1K16 Show the New Immuno ...
HighField Biopharmaceuticals presented positive safety and efficacy findings from its Phase 1 study of HF1K16 (K16), targeting myeloid-derived suppressor cells (MDSCs), at the ESMO Congress 2024. The study showed significant immune modulation and efficacy, with several R/R glioma patients surviving over 2 years.